Rates of first infection following kidney transplant in the United States

Kidney International

Volumn 75, Issue 3, 2009, Pages 317-326

  Snyder, Jon J ^a   Israni, Ajay K ^b,c   Peng, Yi ^a   Zhang, Lin ^d   Simon, Teresa A ^d   Kasiske, Bertram L ^b  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Graft survival; Infections; Kidney transplant

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIALYSIS; FEMALE; HEPATITIS B; HEPATITIS C; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RATE; INFECTION RISK; INFORMATION PROCESSING; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICARE; MYCOSIS; PARASITOSIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SEROLOGY; SEX DIFFERENCE; UNITED STATES; VIRUS INFECTION;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DIABETES MELLITUS; FEMALE; GRAFT SURVIVAL; HUMANS; INCIDENCE; INFECTION; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; VIRUS DISEASES; YOUNG ADULT;

EID: 58349097872     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.580     Document Type: Article

References (62)

1. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States, Volume II. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disorders: Bethesda, MD, 2006 pp 147-148.
2. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States, Volume II. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2006 pp 157-158.
3. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States, Volume I. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2006 pp 155.
4. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States, Volume I. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2006 pp 152.
5. US Renal Data System. USRDS 2005 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2005 pp 152.
6. Abbott KC, Oliver III JD, Hypolite I et al. Hospitalizations for bacterial septicemia after renal transplantation in the United States. Am J Nephrol 2001; 21: 120-127.
7. Abbott KC, Hypolite I, Poropatich RK et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis 2001; 3: 203-211.
8. Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest 2001; 120: 1883-1887.
9. Abbott KC, Hypolite IO, Viola R et al. Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. Ann Epidemiol 2002; 12: 402-409.
10. Gourishankar S, McDermid JC, Jhangri GS et al. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004; 4: 108-115.
11. Safdar N, Slattery WR, Knasinski V et al. Predictors and outcomes of candiduria in renal transplant recipients. Clin Infect Dis 2005; 40: 1413-1421.
12. Dantas SR, Kuboyama RH, Mazzali M et al. Nosocomial infections in renal transplant patients: risk factors and treatment implications associated with urinary tract and surgical site infections. J Hosp Infect 2006; 63: 117-123.
13. Kutinova A, Woodward RS, Ricci JF et al. The incidence and costs of sepsis and pneumonia before and after renal transplantation in the United States. Am J Transplant 2006; 6: 129-139.
14. Kumar D, Humar A, Plevneshi A et al. Invasive pneumococcal disease in solid organ transplant recipients - 10-year prospective population surveillance. Am J Transplant 2007; 7: 1209-1214.
15. US Renal Data System. USRDS 2003 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2003 pp 124.
16. Meier-Kriesche HU, Ojo AO, Hanson JA et al. Exponentially increased risk of infectious death in older renal transplant recipients. Kidney Int 2001; 59: 1539-1543.
17. Alangaden GJ, Thyagarajan R, Gruber SA et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant 2006; 20: 401-409.
18. Dharnidharka VR, Caillard S, Agodoa LY et al. Infection frequency and profile in different age groups of kidney transplant recipients. Transplantation 2006; 81: 1662-1667.
19. Chavers BM, Solid CA, Gilbertson DT et al. Infection-related hospitalization rates in pediatric versus adult patients with end-stage renal disease in the United States. J Am Soc Nephrol 2007; 18: 952-959.
20. Dharnidharka VR, Agodoa LY, Abbott KC. Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients - an analysis of USRDS data. Am J Transplant 2007; 7: 653-661.
21. San Juan R, Aguado JM, Lumbreras C et al. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant 2007; 7: 964-971.
22. US Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States. Volume II ed. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2007 Figure 7.61.
23. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751.
24. Jassal SV, Roscoe JM, Zaltzman JS et al. Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol 1998; 9: 1697-1708.
25. Henry SD, Metselaar HJ, Lonsdale RC et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 2006; 131: 1452-1462.
26. Fabrizi F, Martin P, Dixit V et al. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 2913-2921.
27. Ingsathit A, Thakkinstian A, Kantachuvesiri S et al. Different impacts of hepatitis B virus and hepatitis C virus on the outcome of kidney transplantation. Transplant Proc 2007; 39: 1424-1428.
28. Maluf DG, Fisher RA, King AL et al. Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation 2007; 83: 853-857.
29. Asfandiyar S, Abouljoud M, Kim D et al. Influence of hepatitis C on renal function after liver transplantation. Transplant Proc 2006; 38: 3643-3645.
30. Pedroso S, Martins L, Fonseca I et al. Impact of hepatitis C virus on renal transplantation: association with poor survival. Transplant Proc 2006; 38: 1890-1894.
31. Bloom RD, Lake JR. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transplant 2006; 6: 2232-2237.
32. Perez RM, Ferreira AS, Medina-Pestana JO et al. Is hepatitis C more aggressive in renal transplant patients than in patients with end-stage renal disease? J Clin Gastroenterol 2006; 40: 444-448.
33. Bucci JR, Lentine KL, Agodoa LY et al. Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the United States: analysis of the USRDS/UNOS database. Clin Transpl 2004; 18: 51-61.
34. Manga SG, Sahin S, Kantarci G et al. Impact of hepatitis C virus infection on patient and graft survival in kidney transplantation. Transplant Proc 2006; 38: 499-501.
35. Ozdemir BH, Ozdemir FN, Sezer S et al. De novo glomerulonephritis in renal allografts with hepatitis C virus infection. Transplant Proc 2006; 38: 492-495.
36. Delladetsima I, Psichogiou M, Sypsa V et al. The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: a retrospective follow-up study. Am J Kidney Dis 2006; 47: 309-316.
37. Yuan CH, Liu YF, Li GC. Influence of hepatitis B and hepatitis C virus infection on the outcome of kidney transplantation. Chin Med Sci J 2005; 20: 129-132.
38. Fabrizi F, Martin P, Dixit V et al. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 1452-1461.
39. Batty Jr DS, Swanson SJ, Kirk AD et al. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant 2001; 1: 179-184.
40. Abbott KC, Lentine KL, Bucci JR et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol 2004; 15: 3166-3174.
41. Ridruejo E, Brunet MR, Cusumano A et al. HBsAg as predictor of outcome in renal transplant patients. Medicina (B Aires) 2004; 64: 429-432.
42. Giblin L, Clarkson MR, Conlon PJ et al. Impaired renal allograft, but not patient survival, in patients with antibodies to hepatitis C virus. Ir J Med Sci 2004; 173: 82-84.
43. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004; 78: 745-750.
44. Morales JM, Dominguez-Gil B, Sanz-Guajardo D et al. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal alograft failure. Nephrol Dial Transplant 2004; 19(Suppl 3): iii72-iii76.
45. Ozdemir FN, Micozkadioglu H, Sezer S et al. HCV antibody positivity significantly affects renal allograft survival. Transplant Proc 2003; 35: 2701-2702.
46. Abbott KC, Bucci JR, Matsumoto CS et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14: 2908-2918.
47. Kasiske BL, Snyder JJ, Gilbertson D et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185.
48. Bucci JR, Matsumoto CS, Swanson SJ et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 2002; 13: 2974-2982.
49. Parasuraman R, Yee J, Karthikeyan V et al. Infectious complications in renal transplant recipients. Adv Chronic Kidney Dis 2006; 13: 280-294.
50. Valera B, Gentil MA, Cabello V et al. Epidemiology of urinary infections in renal transplant recipients. Transplant Proc 2006; 38: 2414-2415.
51. Sweny P. Infection and cancer following renal transplantation. Saudi J Kidney Dis Transpl 2006; 17: 189-199.
52. Hellinger WC, Bonatti H, Machicao VI et al. Effect of antiviral chemoprophylaxis on adverse clinical outcomes associated with cytomegalovirus after liver transplantation. Mayo Clin Proc 2006; 81: 1029-1033.
53. Falagas ME, Snydman DR, Griffith J et al. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 1996; 23: 468-474.
54. Paya CV, Wiesner RH, Hermans PE et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18: 185-195.
55. van den Berg AP, Klompmaker IJ, Haagsma EB et al. Evidence for an increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection. Clin Transplant 1996; 10: 224-231.
56. George MJ, Snydman DR, Werner BG et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103: 106-113.
57. Mutimer DJ, Shaw J, O'Donnell K et al. Enhanced (cytomegalovirus) viral replication after transplantation for fulminant hepatic failure. Liver Transpl Surg 1997; 3: 506-512.
58. Nichols WG, Corey L, Gooley T et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273-282.
59. Radisic M, Lattes R, Chapman JF et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis 2003; 5: 84-93.
60. Arend SM, Westendorp RG, Kroon FP et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996; 22: 920-925.
61. Kasiske BL, Snyder JJ, Gilbertson DT et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-913.
62. Stringer JR, Beard CB, Miller RF et al. A new name (Pneumocystis jiroveci) for pneumocystis from humans. Emerg Infect Dis 2002; 8: 891-896.